期刊文献+

萘哌地尔治疗原发性高血压的临床研究 被引量:1

The efficacy of naftopidil in treatment of mild-to-moderate essential hypertension
暂未订购
导出
摘要 目的 :探讨萘哌地尔对轻、中度原发性高血压的疗效和安全性。方法 :40例患者采用开放临床试验 ,安慰剂期 2周、治疗期 8周 ,应用萘哌地尔片 2 5~ 5 0 mg,Bid。结果 :治疗 2周后血压开始下降 ,4周后显示良好的降压效果。收缩压和舒张压的下降幅度分别为 2 .2 8k Pa(17.1mm Hg)和 1.43k Pa(10 .7mm Hg) ,心率无明显变化。降压总有效率 82 .0 5 %。不良反应为头晕 1例。 结论 :萘哌地尔片治疗轻、中度原发性高血压安全、有效 。 Objective: To investigate the efficacy and safety of naftopidil on patients with mild to moderate essential hypertension. Methods: A prospective, open study was performed in patients with hypertension. Forty patients were administered naftopidil for 8 weeks. Results:BP decreased significantly 2 weeks after administration and reached to its trough at week 4. The magnitudes were 2.28 kPa (17.1 mmHg) and 1.43 kPa (10.7 mmHg) for SBP and DBP, respectively. The effect lasted to the end of experiment. HR had no change.The total effective rate was 82.05%.There was no significant change in liver and renal function and electrocardiograph. Conclusion: Naftopidil has a stable hypotensive effect and the compliance is good. [
出处 《第二军医大学学报》 CAS CSCD 北大核心 2001年第2期170-172,共3页 Academic Journal of Second Military Medical University
关键词 萘哌地尔 原发性高血压 药物治疗 naftopidil hypertension
  • 相关文献

参考文献5

  • 1[1]Takei R,Ikegaki I,Shibata K,et al. Naftopidil, a novel alp ha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors[J].J pn J Pharmacol, 1999, 79(4): 447-454.
  • 2[2]Yasuda K, Yamanishi T, Tojo M,et al. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies[ J]. Prostate, 1994, 25(1): 46-52.
  • 3[3]Kirsten R,Breidert M,Nelson K,et al. Naftopidil inhibits 5-hydrox ytryptamine-induced platelet aggregation and 5-hydroxytryptamine uptake in pla telets of healthy volunteers[J]. Eur J Clin Pharmacol, 1994, 46(3): 271-274.
  • 4[4]Kawasaki H, Nakamura S, Takasaki K, et al. Antihypertensive effect of naftopidil (KT-611), a novel alpha 1-adrenoceptor antagonist, in freely movin g experimental hypertensive rats and dogs[J]. Nippon Yakurigaku Zasshi, 1990 , 96(3): 129-139.
  • 5[5]Alarayyed NA,Graham BR,Prichard BN,et al. The potentiation of adre naline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects[J]. Br J Clin Pharmacol, 1995, 39(4): 369-374.

同被引文献18

  • 1Anon. Naftopidil. Drugs Future 1987,12: 31.
  • 2Himmel HM. Naftopidil, a novel antihypertensive drug. Cardiovasc Drug Rev, 1994,12: 32.
  • 3Borbe HO,Peter G. Radioreceptor assay (RRA) for the determination of al - adrenoceptor- binding material in rat plasma following single oral administrator of naftopidil (50 mg/kg).Arzeneim Forsch, 1990,40 : 253.
  • 4Niebch G, Locher M, Borbe HO. Metabolic fate of the novel antihypertensive drug naftopidi. Arznenimittel Forschung,1991,41 (10) : 1027.
  • 5Niebch G,Borbe HO,Besenfelder E. High- performance liquid two chromatography in hurman plasma Naftopidil. J Chromatogr, 1990,534: 247.
  • 6Trakado T, Old E, Iida M, et al. Metabolism of naftopidil(KT-611)in healthy volunteers. J Clin Ther Med. 1992,8(Supp13):S3.
  • 7Farthing MJ, Abrams SM, et al. Pharmacokinetics of naftopidil,a novel anti - hypertensive drug,in patients with hepatic dysfunction. Postgrad Med J, 1994,70(823) :363.
  • 8Takagi N, Ishii M, takeda K, et al. Pharmacokinetics of naftopidil(KT- 611) in hypertensive patients with renal impairment of normal renal function. J Clin Ther Med, 1992,8(Supp13) : s109.
  • 9Nonaka H,Kagoshima T, Dohi K, et al. Effects of naftopidil (KT-611) on renal fumction in patients with essential hypertension. J Clin Ther Med, 1992,8(Supp13) :s89.
  • 10诸俊仁,杨蕊敏.老年医学.陈灏珠,主编.实用内科学.第11版.北京:人民卫生出版社,2001,231.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部